>Opinion Neutre et OC 7.70 € maintenus - Le chiffre d’affaires du T1 24 est ressorti globalement en ligne avec nos attentes (111.1 M€ vs 100.4 M€) porté par les capacités installées en croissance (+47% vs T1 23) en partie compensées par une faiblesse des ressources dans l’éolien brésilien (taux d’utilisation de 27% vs 40%). L’objectif d’EBITDA d’environ 255 M€, dont autour de 230 M€ provenant des ventes d’énergie en 2024, a été confirmé à nouveau. Notre recommandation...
Two Directors at Akzo Nobel N.V. bought 9,282 shares at 64.260EUR. The significance rating of the trade was 93/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
>Une sanction trop sévère ? - Le groupe a tenu sa conf call hier à 15h, et le titre a clôturé à -8% : Le cours avait progressé de 31% sur les 6 derniers mois, créant de facto les conditions de prise de profits, ou éventuellement de short pour les investisseurs les plus critiques de la communication du groupe.Comme lors des résultats annuels, la sanction boursière d’hier nous apparait sévère au regard 1/ de ce qui a été publié au titre du T1 et 2/ de ce qui ...
>Un CA T1 supérieur aux attentes : 2225.5 M€ vs 2144.5 M€ estimés - Au titre de son premier trimestre, le groupe SPIE publie un chiffre d’affaires légèrement supérieur aux attentes. Celui-ci progresse de 11.6% à 2225.5 M€ alors que nous retenions 2144.5 M€ (différence +3.8%) et le consensus 2167 M€ (différence +2.7%). La majorité de l’écart porte sur la croissance organique qui s’élève à +6.2% ce qui est une excellente performance (nous attendions +4.3% et le css +5....
ASMPT’s 1Q24 results are better than expected thanks to strong margins, but 2Q24’s revenue guidance was below our and consensus estimates due to sluggish sales of mainstream tools. Nevertheless, the advanced packaging business remains robust, and we see more positive developments with TCB and HB tools, including progress in leading foundry clients, new order wins, and demo shipments to new HBM clients. Maintain BUY and trim target price to HK$120.00.
A director at DBAPPSecurity Co Ltd maiden bought 4,000 shares at 49.690CNY and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
>Q1 sales at -5.9% with organic growth of just +1.4% - Nestlé posted very poor Q1 results well below expectations which had been already lowered during the last 4 weeks. Reported net sales came in at CHF 22,092m at -5.9% (VA consensus at -3.8% and ODDO BHF at -3.2%) with FX at -6.7%, a scope effect of -0.6% and organic growth at a very low level of +1.4% (VA css at +3.1% and ODDO BHF at +2.6%). Q1 organic growth of just +1.4% was driven by a negative volume mix ...
Inflation is not only sticky in the US but also in Australia and with a very same flavor: prices of tradable goods are disinflating but not those of services. While prices of tradables decelerated sharply to +0.9% YoY in Q1-24, the decline in the headline CPI was limited to +3.6% YoY, which is still above the Reserve Bank of Australia (RBA)’s 2-3% inflation target range (Chart 1). The main reason is that non-tradables (mainly services), which are largely influenced by domestic factors, remained ...
Vianet has published a positive trading update for FY24 with turnover up 7.6% to £15.18m, a 3.5 percentage point increase in gross margin YoY, and adjusted EBITA ahead of market expectations. Net debt continues to fall and closed FY24 at £1.52m (£2.1m at 30 September 2023), demonstrating strong free cash flow generation, even without the benefit of the £0.9m tax receipt received in 1H24, which augers well for a final dividend. The company reported a new contract with Wilcomatic Wash Systems, the...
>Q1 sales at -5.9% with organic growth of just +1.4% - Nestlé posted very poor Q1 results well below expectations which had been already lowered during the last 4 weeks. Reported net sales came in at CHF 22,092m at -5.9% (VA consensus at -3.8% and ODDO BHF at -3.2%) with FX at -6.7%, a scope effect of -0.6% and organic growth at a very low level of +1.4% (VA css at +3.1% and ODDO BHF at +2.6%). Q1 organic growth of just +1.4% was driven by a negative volume mix ...
>Q1 EBITDA up 41% and EBIT up 75% - Fugro this morning published its 24Q1 trading update:- Revenues up comparable up 9.0% y-o-y to € 503.2m (AAOB € 500.9m) with Marine up 13.8% to € 378.2m (AAOB € 363.6m) and Land down 3.5% to € 125.0m (AAOB € 137.2m)- Adjusted EBITDA up 41% y-o-y to € 82.8m (AAOB € 61.1m), equivalent to an EBITDA margin of 16.5% (12.6% a year ago, AAOB 12.2%)- Adjusted EBIT up 75% y-o-y to € 44.2m (AAOB € 21.7m), equivalent to an EBIT ...
Moody's Japan K.K. has withdrawn the A1 LT issuer rating, A1 senior unsecured ratings, and a2 Baseline Credit Assessment of Hamamatsu City. The outlook prior to the withdrawal was stable. RATINGS RATIONALE Moody's has decided to withdraw the ratings for its own business reasons. Please refer to ...
1/4NEWSContact:東京 東京粟野 幸子 セメトコ 真理子主任格付アナリスト/アナリスト 格付責任者/アソシエイト・マネージング・ディレクターサブソブリン・グループ コーポレート・ファイナンス・グループムーディーズ・ジャパン株式会社 ムーディーズ・ジャパン株式会社お客様専用電話番号:03-5408-4100報道関係者電話番号:03-5408-4110お客様専用電話番号:03-5408-4100報道関係者電話番号:03-5408-4110[MJKK]浜松市の格付A1を取下げ 2024年4月25日、東京、ムーディーズ・ジャパン株式会社(以下「ムーディーズ」)は、浜松市の長期発行体...
Futura Medical’s investment case has shifted firmly onto commercial execution. The highly successful initial launches of Eroxon, its novel topical gel for ED (erectile dysfunction), by partner Cooper Consumer Health in the UK and Belgium are now being followed by roll-outs across the major European markets. The much-anticipated launch in the commercially important US market by consumer healthcare giant Haleon is expected before February 2025. Launches in Other Regions are anticipated throughout...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.